LSL Pharma Group Inc (LSL-DB.CA) Stock Fundamental Analysis
Canada - TSX Venture Exchange - TSX-V:LSL-DB -
100 CAD
0 (0%)
LSL-DB gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 4 industry peers in the Personal Care Products industry. LSL-DB has a bad profitability rating. Also its financial health evaluation is rather negative. LSL-DB has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- LSL-DB had negative earnings in the past year.
- In the past year LSL-DB has reported a negative cash flow from operations.
1.2 Ratios
- LSL-DB's Return On Assets of -4.37% is in line compared to the rest of the industry. LSL-DB outperforms 50.00% of its industry peers.
- The Return On Equity of LSL-DB (-8.14%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.37% | ||
| ROE | -8.14% | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- LSL-DB has a Gross Margin of 25.13%. This is comparable to the rest of the industry: LSL-DB outperforms 50.00% of its industry peers.
- LSL-DB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 25.13% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- LSL-DB does not have a ROIC to compare to the WACC, probably because it is not profitable.
- LSL-DB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- An Altman-Z score of 393.87 indicates that LSL-DB is not in any danger for bankruptcy at the moment.
- LSL-DB's Altman-Z score of 393.87 is amongst the best of the industry. LSL-DB outperforms 100.00% of its industry peers.
- LSL-DB has a Debt/Equity ratio of 0.45. This is a healthy value indicating a solid balance between debt and equity.
- LSL-DB has a Debt to Equity ratio of 0.45. This is in the better half of the industry: LSL-DB outperforms 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.45 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 393.87 |
ROIC/WACCN/A
WACC7.66%
2.3 Liquidity
- LSL-DB has a Current Ratio of 1.17. This is a normal value and indicates that LSL-DB is financially healthy and should not expect problems in meeting its short term obligations.
- The Current ratio of LSL-DB (1.17) is worse than 75.00% of its industry peers.
- A Quick Ratio of 0.50 indicates that LSL-DB may have some problems paying its short term obligations.
- LSL-DB has a Quick ratio of 0.50. This is in the lower half of the industry: LSL-DB underperforms 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.17 | ||
| Quick Ratio | 0.5 |
3. Growth
3.1 Past
- LSL-DB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.11%.
EPS 1Y (TTM)-17.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%59.61%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for LSL-DB. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, LSL-DB is valued a bit cheaper than 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 10620.58 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- LSL-DB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LSL Pharma Group Inc / LSL-DB.CA FAQ
What is the ChartMill fundamental rating of LSL Pharma Group Inc (LSL-DB.CA) stock?
ChartMill assigns a fundamental rating of 1 / 10 to LSL-DB.CA.
Can you provide the valuation status for LSL Pharma Group Inc?
ChartMill assigns a valuation rating of 1 / 10 to LSL Pharma Group Inc (LSL-DB.CA). This can be considered as Overvalued.
How profitable is LSL Pharma Group Inc (LSL-DB.CA) stock?
LSL Pharma Group Inc (LSL-DB.CA) has a profitability rating of 1 / 10.
What is the financial health of LSL Pharma Group Inc (LSL-DB.CA) stock?
The financial health rating of LSL Pharma Group Inc (LSL-DB.CA) is 3 / 10.